J&J Submits sBLA to FDA for Rybrevant Combination Therapy in Non-Small Cell Lung Cancer
December 22, 2023
🌧️Trending News
Johnson & Johnson ($NYSE:JNJ) (J&J) is a multinational healthcare company that develops and sells a wide range of medical products, including pharmaceuticals, consumer packaged goods, and medical devices. Listed on the New York Stock Exchange, it is one of the world’s most valuable companies. Recently, J&J submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Rybrevant in combination with chemotherapy for the treatment of non-small cell lung cancer. The FDA’s acceptance of J&J’s sBLA means that Rybrevant may soon be approved as a treatment option for those suffering from non-small cell lung cancer.
If approved, it could become an important combination therapy option in the management of this disease. It would be a great achievement for J&J, as well as for those suffering from non-small cell lung cancer who may soon have access to a potentially effective treatment.
Share Price
On Thursday, JOHNSON & JOHNSON stock opened at $153.7 and closed at $154.8, up by 1.0% from the previous closing price of 153.3. This increase in share prices was due to the company’s submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for their Rybrevant combination therapy for metastatic non-small cell lung cancer (NSCLC). Such approval would expand the current indications for using Rybrevant in NSCLC patients. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for JNJ. More…
| Total Revenues | Net Income | Net Margin |
| 98.66k | 34.62k | 13.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for JNJ. More…
| Operations | Investing | Financing |
| 23.42k | -6.19k | -18.02k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for JNJ. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 179.23k | 108.96k | 29.19 |
Key Ratios Snapshot
Some of the financial key ratios for JNJ are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 6.9% | 7.9% | 24.4% |
| FCF Margin | ROE | ROA |
| 24.3% | 21.4% | 8.4% |
Analysis
At GoodWhale we have done a full financial analysis of JOHNSON & JOHNSON. Our Star Chart gives JOHNSON & JOHNSON a strong rating for dividends, profitability, and a medium rating for assets. Growth is the only area where they are weak. In terms of overall health, our score for JOHNSON & JOHNSON is 9/10. This takes into consideration the company’s cashflows and debt, and how they are able to pay off debt and fund future operations. Given all these factors, we have classified JOHNSON & JOHNSON as a ‘cow’, a company with a track record of paying out consistent and sustainable dividends. Investors who are looking for long-term, stable investments may find JOHNSON & JOHNSON to be an attractive option. More…
Peers
The competition between Johnson & Johnson and its competitors is fierce. AstraZeneca PLC, Pfizer Inc, and BioNTech SE are all major players in the pharmaceutical industry, and they are all vying for a piece of the pie. Johnson & Johnson is a well-established company with a long history of success, but its competitors are not to be underestimated. They are all large, well-funded companies with a lot to lose if they don’t win the competition.
– AstraZeneca PLC ($LSE:AZN)
AstraZeneca PLC is a biopharmaceutical company with a market cap of 152.13B as of 2022. The company focuses on the discovery, development, and commercialization of small molecule drugs in the areas of oncology, cardiovascular, and renal & metabolism. The company’s ROE for the year ended December 31, 2020 was -0.94%.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a pharmaceutical company with a market cap of 240.55B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The company’s products include prescription and over-the-counter medicines, vaccines, and biologic therapies.
– BioNTech SE ($NASDAQ:BNTX)
BioNTech SE is a German biotech company founded in 2008 that focuses on the development of Innovation therapies against cancer and other serious diseases. The company has a market cap of 32.91B as of 2022 and a Return on Equity of 71.82%. BioNTech’s mission is to revolutionize the treatment of cancer and other serious diseases by leveraging the power of the immune system. The company is developing a portfolio of immunotherapy products based on its proprietary mRNA technology platform.
Summary
Johnson & Johnson (J&J) recently submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for its Rybrevant combination therapy in non-small cell lung cancer (NSCLC). If approved, the drug combination may offer an alternative treatment option to patients with advanced NSCLC who have certain genetic mutations. J&J’s stock price could increase with the FDA’s approval of Rybrevant, making it an attractive option for investors seeking to benefit from a potential break-through therapy. Other factors investors should consider when evaluating J&J stock include their diversified product portfolio, strong financial performance, and excellent track record in research and development.
Related Posts
Recent Posts
